BLPH - Bellerophon Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
0.6870
-0.0029 (-0.43%)
As of 3:27PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.6899
Open0.6872
Bid0.68690 x 800
Ask0.68700 x 800
Day's Range0.6803 - 0.6900
52 Week Range0.4700 - 3.3000
Volume101,047
Avg. Volume433,915
Market Cap47.336M
Beta (3Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.73500
Earnings DateMar 13, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire22 days ago

    Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients  

    Actigraphy is Being Utilized to Evaluate Multiple Clinically Meaningful Activity Parameters in the Ongoing INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary.

  • GlobeNewswire25 days ago

    Bellerophon Announces Closing of $7 Million Public Offering of Common Stock

    Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the closing and funding of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.70 per share, less underwriting discounts and commissions. The Company has also granted the underwriter a 45-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The Company’s Chairman, Jonathan M. Peacock, and directors Naseem Amin and Ted Wang each purchased shares in the offering.  The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are $7 million, assuming no exercise of the underwriter’s option to purchase additional shares.

  • GlobeNewswire27 days ago

    Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock

    Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.70 per share, less underwriting discounts and commissions. The Company also granted the underwriter a 45-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. Bellerophon expects to receive aggregate gross proceeds of $7 million from the offering, assuming no exercise of the underwriter’s option to purchase additional shares.

  • GlobeNewswire28 days ago

    Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

    Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.  Bellerophon also intends to grant the underwriter a 45-day option to purchase additional shares of its common stock equal to 15% of the shares to be sold in the offering to cover over-allotments, if any. Bellerophon intends to use the net proceeds from this offering to fund working capital and other general corporate purposes and pursuit of our other research and development efforts. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (“SEC”) and was declared effective on July 6, 2018.

  • GlobeNewswirelast month

    Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

    WARREN, N.J., Jan. 07, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced.

  • GlobeNewswire3 months ago

    DBV Technologies Appoints Daniel Tassé as Chief Executive Officer

    DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq: DBVT), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has unanimously appointed Daniel Tassé as its Chief Executive Officer (CEO) effective November 29, 2018. Dr. Pierre-Henri Benhamou, who co-founded the Company in 2002, will retire as CEO and serve as Non-Executive Chairman of the Board.

  • Associated Press3 months ago

    Bellerophon Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the Warren, New Jersey-based company said it had profit of 10 cents. Earnings, adjusted for non-recurring costs, came to 18 cents per share. The company's shares closed at 90 cents. ...

  • ACCESSWIRE5 months ago

    3 Biotech & Marijuana Stocks to Pay Attention to this Quarter

    GTBiopharma (GTBP), for instance has been building a biopharmaceutical pipeline targeting everything from pain management to cancer treatments. This therapy targets cancer cells expressing the CD19 receptor and/or CD22 receptors, which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploys its cytotoxic diphtheria toxin payload, which inhibits protein synthesis and kills the cancer cells.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch:Tesla and Bellerophon Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 20, 2018 / Tesla shares were hammered on Friday after CEO Elon Musk revealed to the New York Times that the stress of his job is getting to him. Shares of Bellerophon Therapeutics saw unusual activity, climbing over 20% despite any news. Tesla, Inc. shares plummeted nearly 9% on Friday.

  • Benzinga6 months ago

    The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on Aug. 7) Akcea Therapeutics Inc (NASDAQ: AKCA )(reacted to Q2 earnings ...

  • Associated Press7 months ago

    Bellerophon Therapeutics: 2Q Earnings Snapshot

    The Warren, New Jersey-based company said it had a loss of 20 cents per share. The company's shares closed at $2.50. A year ago, they were trading at $1.30. _____ This story was generated by Automated ...

  • 5 Biotech Stocks Under $10 Worthy of Investors' Attention
    Zacks8 months ago

    5 Biotech Stocks Under $10 Worthy of Investors' Attention

    Small biotech stocks are good bets with lower market cap as well as share price.

  • The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp
    Zacks8 months ago

    The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp

    The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp

  • InvestorPlace8 months ago

    5 Top-Ranked Small Caps to Buy as Trade Tensions Escalate

    In the latest edition of the drama on trade and tariffs, President Trump upped the ante against traditional U.S. allies on Monday. In a series of tweets, he attacked Canada and European trading partners, accusing them of heavy tariffs on U.S. products. Additionally, these are likely to benefit the most from the Trump administration’s tax cuts.

  • Bet on 5 Top-Ranked Small Caps as Trade Tensions Escalate
    Zacks8 months ago

    Bet on 5 Top-Ranked Small Caps as Trade Tensions Escalate

    With trade-related tensions refusing to die down, small-cap stocks are looking like an increasingly attractive proposition.